2524 related articles for article (PubMed ID: 32150618)
1. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Yao X; Ye F; Zhang M; Cui C; Huang B; Niu P; Liu X; Zhao L; Dong E; Song C; Zhan S; Lu R; Li H; Tan W; Liu D
Clin Infect Dis; 2020 Jul; 71(15):732-739. PubMed ID: 32150618
[TBL] [Abstract][Full Text] [Related]
2. Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2.
Uzunova K; Filipova E; Pavlova V; Vekov T
Biomed Pharmacother; 2020 Nov; 131():110668. PubMed ID: 32861965
[TBL] [Abstract][Full Text] [Related]
3. The possible mechanisms of action of 4-aminoquinolines (chloroquine/hydroxychloroquine) against Sars-Cov-2 infection (COVID-19): A role for iron homeostasis?
Quiros Roldan E; Biasiotto G; Magro P; Zanella I
Pharmacol Res; 2020 Aug; 158():104904. PubMed ID: 32430286
[TBL] [Abstract][Full Text] [Related]
4. Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2.
Hoffmann M; Mösbauer K; Hofmann-Winkler H; Kaul A; Kleine-Weber H; Krüger N; Gassen NC; Müller MA; Drosten C; Pöhlmann S
Nature; 2020 Sep; 585(7826):588-590. PubMed ID: 32698190
[TBL] [Abstract][Full Text] [Related]
5. In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect.
Andreani J; Le Bideau M; Duflot I; Jardot P; Rolland C; Boxberger M; Wurtz N; Rolain JM; Colson P; La Scola B; Raoult D
Microb Pathog; 2020 Aug; 145():104228. PubMed ID: 32344177
[TBL] [Abstract][Full Text] [Related]
6. Safety considerations for chloroquine and hydroxychloroquine in the treatment of COVID-19.
Gevers S; Kwa MSG; Wijnans E; van Nieuwkoop C
Clin Microbiol Infect; 2020 Sep; 26(9):1276-1277. PubMed ID: 32422406
[No Abstract] [Full Text] [Related]
7. A review on possible modes of action of chloroquine/hydroxychloroquine: repurposing against SAR-CoV-2 (COVID-19) pandemic.
Tripathy S; Dassarma B; Roy S; Chabalala H; Matsabisa MG
Int J Antimicrob Agents; 2020 Aug; 56(2):106028. PubMed ID: 32450198
[TBL] [Abstract][Full Text] [Related]
8. Advances in the use of chloroquine and hydroxychloroquine for the treatment of COVID-19.
Sun J; Chen Y; Fan X; Wang X; Han Q; Liu Z
Postgrad Med; 2020 Sep; 132(7):604-613. PubMed ID: 32496926
[TBL] [Abstract][Full Text] [Related]
9. COVID-19 prevention and treatment: A critical analysis of chloroquine and hydroxychloroquine clinical pharmacology.
White NJ; Watson JA; Hoglund RM; Chan XHS; Cheah PY; Tarning J
PLoS Med; 2020 Sep; 17(9):e1003252. PubMed ID: 32881895
[TBL] [Abstract][Full Text] [Related]
10. Insights from nanomedicine into chloroquine efficacy against COVID-19.
Hu TY; Frieman M; Wolfram J
Nat Nanotechnol; 2020 Apr; 15(4):247-249. PubMed ID: 32203437
[TBL] [Abstract][Full Text] [Related]
11. Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates.
Maisonnasse P; Guedj J; Contreras V; Behillil S; Solas C; Marlin R; Naninck T; Pizzorno A; Lemaitre J; Gonçalves A; Kahlaoui N; Terrier O; Fang RHT; Enouf V; Dereuddre-Bosquet N; Brisebarre A; Touret F; Chapon C; Hoen B; Lina B; Calatrava MR; van der Werf S; de Lamballerie X; Le Grand R
Nature; 2020 Sep; 585(7826):584-587. PubMed ID: 32698191
[TBL] [Abstract][Full Text] [Related]
12. ChemoPROphyLaxIs with hydroxychloroquine For covId-19 infeCtious disease (PROLIFIC) to prevent covid-19 infection in frontline healthcare workers: A structured summary of a study protocol for a randomised controlled trial.
McEniery CM; Fisk M; Miles K; Kaloyirou F; Hubsch A; Smith J; Wilkinson IB; Cheriyan J
Trials; 2020 Jul; 21(1):604. PubMed ID: 32616067
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
[TBL] [Abstract][Full Text] [Related]
14. New Anti SARS-Cov-2 Targets for Quinoline Derivatives Chloroquine and Hydroxychloroquine.
Gentile D; Fuochi V; Rescifina A; Furneri PM
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32824072
[TBL] [Abstract][Full Text] [Related]
15. Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system.
Yuan S; Chan JFW; Chik KKH; Chan CCY; Tsang JOL; Liang R; Cao J; Tang K; Chen LL; Wen K; Cai JP; Ye ZW; Lu G; Chu H; Jin DY; Yuen KY
Pharmacol Res; 2020 Sep; 159():104960. PubMed ID: 32473310
[TBL] [Abstract][Full Text] [Related]
16. COVID-19 Pandemic - A Narrative Review of the Potential Roles of Chloroquine and Hydroxychloroquine.
de Barros CM; Almeida CAF; Pereira B; Costa KCM; Pinheiro FA; Maia LDB; Trindade CM; Garcia RCT; Torres LH; Diwan S; Boralli VB
Pain Physician; 2020 Aug; 23(4S):S351-S366. PubMed ID: 32942793
[TBL] [Abstract][Full Text] [Related]
17. Broad spectrum anti-coronavirus activity of a series of anti-malaria quinoline analogues.
Persoons L; Vanderlinden E; Vangeel L; Wang X; Do NDT; Foo SC; Leyssen P; Neyts J; Jochmans D; Schols D; De Jonghe S
Antiviral Res; 2021 Sep; 193():105127. PubMed ID: 34217752
[TBL] [Abstract][Full Text] [Related]
18. Chloroquine and its derivatives in the management of COVID-19: A scoping review.
Pimentel J; Andersson N
Biomedica; 2020 Oct; 40(Supl. 2):80-95. PubMed ID: 33152192
[TBL] [Abstract][Full Text] [Related]
19. Primum non nocere - Are chloroquine and hydroxychloroquine safe prophylactic/treatment options for SARS-CoV-2 (covid-19)?
Biguetti C; Marrelli MT; Brotto M
Rev Saude Publica; 2020; 54():68. PubMed ID: 32638884
[TBL] [Abstract][Full Text] [Related]
20. Of chloroquine and COVID-19.
Touret F; de Lamballerie X
Antiviral Res; 2020 May; 177():104762. PubMed ID: 32147496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
